ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of ...

According to CBDT data, STT collections stood at Rs 35,682 crore as of Nov. 10, 2025, marginally lower than Rs 35,923 crore ...

Revenues: Revenue for the three months ended September 30, 2025 was $3.7 million, compared to $2.3 million in the same period in 2024. The increase of $1.4 million in revenue resulted from a $1.5 ...

Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –– In addition to ...

As Trump shifts his tone on Chinese students, Beijing doubles down on AI education—signaling a new kind of cold war in ...

Infinidat, a leading provider of enterprise storage solutions, today announced that the company has won three Top InfoSec Innovator Awards for 2025 from Cyber Defense Magazine, a leading information ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...

U.S. data center demand is in a period of unprecedented acceleration driven by AI, cloud scale-outs, and digital ...

In a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMS Full data from both studies will be shared at ...

Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week ...

Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...